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Continuous Infusion of Interleukin- i p  in Rats 
Induces a Profound Fall in Plasma Levels of 
Cholesterol and Triglycerides
Ad R.M.M. Hermus, C.G.J. Sweep, Pierre N.M. Demacker, Mike J.M. van der Meer,
Peter W.C. Kloppenborg, and Jos W.M. van der Meer
During infectious diseases, striking alterations in plasma concentrations of cholesterol (hypocholester- 
olemia) and triglycerides (hypertriglyceridemia) may occur. It has been suggested that interleukin-1 is a 
mediator of these alterations. We studied the effects of continuous administration of recombinant human 
interleukin-l/S (rhIL-1/3) on plasma levels of cholesterol and triglycerides. A total of 42 rats were equipped 
with minipumps loaded with either rhIL-1/3 (delivery rate of 0.5, 2.0, or 4.0 /jlg/day i.p. for 1 week) or 
saline. After 1 day of treatment with rhIL-1/3, plasma cholesterol levels had not changed. On day 2 a 
remarkable decrease of plasma cholesterol levels was observed in rats treated with 2.0 /¿g rhIL-l/3/day 
(1.49±0.13 versus 2.23±0.08 mmol/1, p < 0.005; rhlL-ljS versus saline) or 4.0 /xg rhIL-I/3/day (1.46±0.04 
versus 2.18±0.04 mmol/I,/?<0.0005). This decrease persisted until the end of the experiment and occurred 
in all major lipoprotein fractions. Triglycerides in plasma (and in very low density lipoprotein) decreased 
almost concomitantly with plasma cholesterol, although to a lesser degree. Infusion of 2.0 /xg rhIL-l/3/day 
did not affect either cholesterol esterification or total postheparin lipolytic activity in plasma. Long-term 
infusion with 4.0 /jlg rhIL-l/3/day induced prolonged fever, whereas at the lower doses temperatures were 
elevated only the first 2 days. rhIL-1/3 at a dose of 2.0 and 4.0 /ig/day induced a transient decrease of food 
intake and a suppression of body weight gain. Restriction of food consumption to the level observed in the
2.0 fjLg rhIL-1/3 experiment caused only a small decrease of plasma cholesterol level and had no effects on 
plasma concentrations of triglycerides. Therefore, it is unlikely that the decline in triglyceride levels 
during rhIL-1/3 infusion was caused by a decrease in food intake. Diminished food consumption also 
cannot completely explain the profound decline of cholesterol levels during rhIL-1/3 administration. 
Whether IL-1 plays a role as a mediator of the lowering of plasma cholesterol levels during infections 
remains to be determined. (Arteriosclerosis and Thrombosis 1992;12:1036-1043)
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D uring infectious diseases, striking alterations in 
the plasma concentrations of cholesterol and 
triglycerides may occur in both humans and 
laboratory animals. Except for studies of rabbits,1,2 most 
reports show that plasma cholesterol levels are decreased 
during the febrile phase of bacterial infections.3-8 The 
mechanism causing hypocholesterolemia during infectious 
diseases is unknown. In contrast, plasma levels of triglyc­
erides are usually elevated in bacterial, viral, and parasitic 
infections, particularly during recovery.8-12 In animal 
models of infection a decrease in the catabolism of circu­
lating triglyceride-rich lipoproteins has been observed.13
From  the D e p a r tm e n t  of M edicine, Divisions of Endocrino logy  
(A .R .M .M .H .,  C.G.J.S., M .J.M . van d e r  M., P.W .C.K.) and  G e n ­
eral In te rna l  M edicine (P .N .M .D ., J .W .M . van de r  M.), and the 
D e p a r tm e n t  o f E x p e r im e n ta l  and  C hem ica l  E n d o c r in o lo g y  
(C .G .J.S .), Sint R ad b o u d  University  H ospital,  Nijmegen, T he  
N ether lands .
S upported  by the Royal N e th e r lan d s  A cadem y o f  A rts  and 
Sciences.
A ddress  for co rrespondence :  A d  R .M .M . H erm us,  M D , D e p a r t ­
m en t  o f  M edicine, Division of Endocrinology, Sint R ad b o u d  
U niversity  Hospital,  G e e r t  G roo tep le in  Z u id  8, 6500 H B  N ijm e­
gen, T h e  N etherlands .
Received D e c e m b e r  10, 1991; revision accep ted  May 27, 1992.
Other studies have emphasized the role of increased 
hepatic synthesis of such particles during infection.1415 
Cerami and coworkers (Kawakami and Cerami16 and 
Kawakami et al17) were the first to suggest that macro­
phage factors are important mediators of the hypertriglyc­
eridemia of infection. Their hypothesis was based on the 
observation that endotoxin-stimulated mouse macro­
phages secrete a factor that decreases the activity of 
adipose tissue lipoprotein lipase (LPL) as well as the 
synthesis and storage of lipids in cultured fat cells.1617 In 
later studies this macrophage factor was identified as 
tumor necrosis factor (TNF).18 Further indirect evidence 
for the concept that TNF is an important mediator of the 
hypertriglyceridemia of infection came from a series of 
studies conducted by Feingold and Grunfeld. These re­
searchers showed that administration of TNF to rodents 
produces hypertriglyceridemia mainly by increased he­
patic synthesis of triglyceride-rich lipoproteins.19-23
Interleukin-1 (IL-1) is a cytokine that shares with 
TNF a variety of important biological effects.24 In­
creased levels of both cytokines have been measured in 
biological fluids of patients suffering from infections.25,26 
Although the effects of TNF have been extensively 
studied, only a few reports have focused on the effects of 
IL-1 on lipid metabolism. Recently it was demonstrated
Hermus et al Long-term IL-1/3 Infusion and Lipid Metabolism 1037
that a single bolus injection of IL-1 causes hypertriglyc­
eridemia in rats.27,28 These short-term studies dem on­
strate that IL-1, like TNF, is a potential mediator of the 
hypertriglyceridemia of infection. Until now no data 
have been available with respect to the effects of 
ong-term administration of IL-1 on plasma cholesterol 
ind triglyceride levels in rats. Although IL-1 is likely 
released in a pulsatile fashion during most infections, 
iong-term administration of IL-1 is of interest because 
n some infections and especially in chronic inflamma- 
ion, IL-1 may be released in a more continuous fash- 
on. Such a long-term study is also relevant because 
apid development of tolerance with respect to a num- 
er of biological effects of IL-1 occurs during long-term 
Jministration of this peptide.29-30 In this study we show 
lat long-term intraperitoneal administration of rela- 
vely low doses of IL-1 to rats for 1 week caused a 
rofound decrease of plasma cholesterol levels as well 
s a moderate decline in triglyceride levels.
M ethods
•si Materials
Recombinant human IL-1/3 (rhIL-1/3) was kindly 
ovided by Dr. D. Boraschi (Sclavo, Siena, Italy). The 
eparation had a specific activity of 109 units/mg pro- 
n on D10.G4.1 cells, corresponding to an activity of 
units//xg versus the interim IL-1/3 reference reagent 
552. According to the specifications of the suppliers, 
dotoxin contamination was negligible (<1.2  ng lipo- 
ysaccharide/mg IL-1). rhIL-1/3 was diluted in sterile 
ogen-free saline.
\nimals
vlale albino Wistar rats (Cpb:WU) were obtained 
In m a local breeding facility. They were housed in an 
iii’i ificially lighted room (lights on at 7 am and off at 7
i n in individual Plexiglas cages. Rats were fed with 
nmercial rat chow (RM H-TM , Hope Farms, Woer- 
d e n ,  The Netherlands) and tap water ad libitum. The 
di t contained 22% protein, 4.8% fat, 5.1% fiber, and 
61 % other carbohydrates. At the start of the experi­
ments rats were 10 weeks old and weighed 200-220 g.
experimental procedures were in accordance with 
institutional guidelines concerning the care and use of 
laboratory animals.
/-..vperimental Protocols
Long-term administration o f rhIL-lp. To accommo- 
d the animals to the stress of the experimental 
procedures, they were handled daily by the experi- 
menter starting 1 week before venous cannulation. Body 
v uht was measured daily at 8 am, and food and water 
in ike was recorded by weighing the residual food and 
water for individual cages. Body temperature was m ea­
sured serially two times a day between 8:30 and 9 am 
and between 1 and 2:30 pm in conscious hand-held rats 
insertion of a thermal probe into the rectum. The 
probe was connected to a digital tem perature monitor 
(digital DT100, Elbatron, Kerkdriel, The Netherlands). 
Mean daily tem perature for each rat was determined by 
averaging the morning and afternoon rectal tem pera­
tures. Blood was collected from freely moving rats by 
means of an indwelling cannula. Rats were cannulated 
as described by Steffens.31 U nder anesthesia with pen­
tobarbital (60 mg/kg body wt i.p., Apharma, Arnhem, 
The Netherlands) and atropine (0.125 mg/kg body wt 
i.m., Pharmachemie, Haarlem, The Netherlands), a 
Silastic cannula (0.5 mm i.d., 0.94 mm o.d., Dow- 
Corning Corp., Midland, Mich.) was inserted into the 
right external jugular vein under sterile conditions and 
passed down to the atrium. The distal end of the 
cannula was tunneled subcutaneously and exteriorized 
through a stab wound in the skin of the head, where it 
was connected to a hooked stainless steel tube. This 
assembly was anchored to the skull with three stainless 
steel screws and acrylic cement. During cannulation, 
the rats were continuously exposed to a gas flow of 
0 2/N20 .  The cannula was filled with a 0.9% NaCl 
solu tion  con ta in ing  500 IU/ml hepa r in  (T hrom - 
boliquine, Organon Teknika, Boxtel, The Netherlands) 
and polyvinylpyrrolidone (1 g/ml, Merck, Darmstadt, 
FRG).
Seven to nine days after cannulation, rats were 
equipped with intraperitoneal osmotic minipumps (2 to
4 pm). The osmotic pumps (1 /xl/hr, model 2001, Alzet 
Corp., Palo Alto, Calif.) were loaded before implanta­
tion with rhIL-1/3 dissolved in sterile, pyrogen-free 
physiological saline or with saline alone, subsequently 
equilibrated, and immersed in saline for 3 - 4  hours at 
37°C according to the instructions of the manufacturer. 
Three separate experiments, each including 14 animals, 
were performed. In each experiment one group of rats 
{n = l)  was continuously infused at a rate of 0.5, 2.0, or
4.0 fig rhIL-l/3/day, and a control group (n = 7) received 
osmotic pumps filled with 0.9% pyrogen-free saline. The 
indwelling cannula and the osmotic pump were well 
tolerated by the animals with no signs of discomfort or 
infection.
Blood samples for determination of plasma choles­
terol and triglyceride levels were collected daily from 
freely moving, nonfasted rats by means of the jugular 
cannula between 10 am and noon for 10 days starting 2 
days before implantation of the pumps. Blood samples 
were collected in prechilled tubes containing dry lithi- 
um-heparin additive (Vacutainer, 30 USP units/tube, 
Becton Dickinson, Etten-Leur, The Netherlands). In 
the 2.0 fig rhIL-1/3 experiment additional blood was 
sampled for lipoprotein analysis, for determination of 
the ratio of unesterified to total cholesterol in plasma, 
and for determination of the rate of cholesterol esteri- 
fication in vitro on day 5 after implantation of the 
minipumps. On day 7 of this experiment postheparin 
plasma samples were obtained in E D T A  (1 mg/ml) 15 
minutes after intravenous injection of 100 IU hepa­
rin/kg body wt (Thromboliquine, Organon Teknika). 
Blood samples were gently shaken and spun for 10 
minutes at l,50Qg (4°C). Plasma was separated, and the 
red blood cells were resuspended in sterile physiological 
saline and returned to each rat. Plasma samples were 
apportioned into aliquots and stored at -2 0 °C  until 
assayed.
Effects o f food restriction on plasma levels o f cholesterol 
and triglycerides. To investigate whether the rhIL-1/3- 
induced changes in plasma cholesterol and triglyceride 
levels could be explained solely by the decrease in food 
intake observed in the rhIL-l/3-infused rats, a fourth 
experiment was performed. In this experiment rats 
equipped with a jugular cannula underwent the same 
surgical procedure on day 0 as the rats in the first three
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experiments but without implantation of osmotic mini­
pumps. One group of animals (/z = 6) received food ad 
libitum, whereas another group (n=7) was fed daily 
with the same amount of food that had been consumed 
on that particular day of the experiment by rats treated 
with 2.0 fig rhIL-l/3/day (food-restricted group). Plasma 
levels of cholesterol and triglycerides as well as food 
intake and body weight were measured daily for 1 week.
Analytical Methods
Plasma levels of triglycerides and cholesterol were 
determined by enzymatic methods by using a BM/ 
Hitachi 717 automatic analyzer system and Boehringer 
M annheim  (M annheim, F R G ) diagnostic kits No. 
1058550 (for triglycerides) and No. 1040839 (for choles­
terol). The very low density lipoprotein (VLDL) plus 
intermediate density lipoprotein (IDL) (d< 1.019 g/ml), 
low density lipoprotein (LDL, 1 .019<d< 1.070 g/ml), 
and high density lipoprotein (HDL, d>  1.070 g/ml) 
fractions were isolated by sequential ultracentrifugation 
for 18 hours at 168,000g. By previous density gradient 
ultracentrifugation and electrophoretic studies, the 
density of 1.070 g/ml was found to give an accurate 
separation of LDL from H D L  in rat plasma. LPL and 
hepatic lipase (HL) in postheparin plasma samples were 
measured selectively by a method that uses a gum 
arabic-stabilized emulsion of triolein and [3H]triolein.32 
With the substrate containing 0.1 M NaCl and an 
optimal amount of dialyzed human serum to provide 
activating apolipoprotein C-II, total triglyceride lipase 
activity (L P L + H L ) was measured. HL was determined 
in the same substrate at a sodium chloride concentra­
tion of 1 M with omission of the serum activator. LPL 
was determined by subtraction. The assays were per­
formed by incubating 10 /xl postheparin plasma with 250 
/xl of either substrate for 30 minutes at 30°C. The rate of 
cholesterol esterification by lecithin: cholesterol acyl- 
transferase (LCAT) was measured by estimating the 
decrease in unesterified cholesterol during incubation 
of plasma at 37°C for 1 and 3 hours.33 Plasma unester­
ified cholesterol was measured by an enzymatic method 
with diagnostic kit No. 310328 from Boehringer M ann­
heim. All incubations were performed in duplicate with 
undiluted plasma.
Statistical Analysis
In each experiment a few rats had to be excluded 
because of blood clotting within the cannulas. All data 
are presented as m ean ± S E M  of five to seven rats. 
Comparisons between treatment groups were made by 
analysis of variance (ANOVA) with repeated m easure­
ments to analyze the effects of the treatment course. 
Only when the A N O V A  revealed a significant differ­
ence between both groups was a comparison of the 
groups at specific time points evaluated further by 
S tudent’s t test for unpaired observations.
Results
Results o f  Long-term Treatment 
o f  Rats With rh IL -l(l
Physical discomfort. Signs of physical discomfort in­
cluding piloerection and decreased physical activity 
were observed in animals infused with 4.0 fig rhIL-1/3/ 
day starting a few hours after implantation of the
pumps. This visually observed uneasiness gradually di­
minished during the first day of the treatment period 
and had disappeared by the end of day 1. Infusion with
2.0 f i g  rhIL-l/3/day also induced signs of discomfort that 
were less pronounced than those induced by the 4.0 /xg 
rhIL-1/3 dose. Treatm ent of rats with 0.5 /xg rhIL-1/3/ 
day or with saline did not perceptibly distress the 
animals.
Plasma levels o f cholesterol and triglycerides (Figure 1). 
Figure 1A shows that from day 2 after implantation of 
the minipumps, plasma cholesterol levels in rats treated 
with 0.5 /xg rhIL-l/3/day were slightly but not signifi­
cantly lower than those in rats treated with saline. After 
1 day of treatment with 2.0 or 4.0 f i g  rhIL-l/3/day, 
plasma cholesterol levels had not changed. From day 2 
onward a remarkable decrease in plasma cholesterol 
levels was observed in rh IL -l /3 - trea ted  rats, which 
persisted until the end of the experiment (Figures 1C 
and IE; A N O V A  days 2-7, 2.0 /xg rhIL-1/3 experiment, 
p<0.0005; 4.0 fig rhIL-1/3 experiment, p<0.0005). 
Plasma cholesterol levels in rh IL -l /3 - trea ted  rats were 
significantly decreased from day 2 (2.0 /xg rhIL-1/3 
experim ent,  1 .49±0.13 versus 2 .23±0 .08  mmol/1, 
p < 0.005; 4.0 /xg rhIL-1/3 experiment, 1.46±0.04 versus 
2.18±0.04 mmol/1, /?<0.0005; rhIL-1/3 versus saline) up 
to and including day 7 (2.0 /xg rhIL-1/3 experiment, 
1.71 ±0.07 versus 2.09±0.04 mmol/1, p<0.005; 4.0 f ig  
rhIL-1/3 experim ent,  1 .57±0.05 versus 2.15±0.05 
mmol/1, /?<0.0005; rhIL-1/3 versus saline).
Treatm ent with rhIL-1/3 also induced a decrease in 
plasma levels of triglycerides (Figures IB, ID, and IF; 
A N O V A  days 1-7, 0.5 /xg rhIL-1/3, /?<0.10; 2.0 f ig  
rhIL-1/3, /?<0.05; 4.0 /xg rhIL-1/3, p<0.05).  In contrast 
with the decrease in cholesterol level, which persisted 
until the end of the infusion, the decline in triglyceride 
levels was diminishing at the end of the infusion period. 
Statistically significant differences in plasma levels of 
triglycerides were observed on days 1-4  during treat­
ment with 2.0 f i g  rhIL-l/3/day and on days 1-3 and 5-7 
during treatment with 4.0 /xg rhIL-l/3/day. Although 
blood samples were not taken from previously fasted 
rats, chylomicrons appeared to be absent, as evidenced 
by agarose gel electrophoresis (data not shown).
Suppression o f food intake and daily body weight change 
(Figure 2). In saline-treated rats there was a slight 
reduction in food intake 1 day after implantation of the 
minipumps. Long-term treatment of rats with 0.5 f ig  
rhIL-l/3/day did not affect daily food intake. Analysis of 
repeated measures (days 1-7) revealed a depressive 
effect on food consumption associated with treatment 
with the higher doses of rhIL-1/3 (2.0 /xg rhIL-1/3, 
p < 0.05; 4.0 f i g  rhIL-1/3, p<0.0005). One day after 
implantation of the pumps, the decrease in food intake 
was maximal (2.0 f i g  rhIL-1/3, 4.4±1.6 versus 11.6± 1.7 
g, rhIL-1/3 versus saline, /?<0.05; 4.0 f i g  rhIL-1/3, 
5.5±0.9 versus 13.7±0.9 g, p<0.0005). Food intake 
remained significantly lower in rh IL -l /3 - trea ted  than in 
control animals up to and including days 3 (2.0 /xg) and
5 (4.0 f i g ) .
There was only a small (0.5 f i g  rhIL-1/3, —3.4± 1.8 g ;
2.0 f i g  rhIL-1/3, —7.1 ±1.9 g) or no (4.0 f i g  rhIL-1/3) 
decrease in body weight on the first day of s a l i n e  
infusion (Figure 2). Infusion of rats with 0.5 f i g  rhlL-
1 /3/day did not notably affect daily body weight c h a n g e  
compared with saline infusion. Continuous infusion of
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F i g u r e  1. L/>ze showing 
effects o f continuous infusion o f  
different doses o f recombinant 
human interleukin-1 ß  (IL1) (0.5 
(panels A and B), 2.0 (panels C 
and D), and 4.0 (panels E and 
F )  fig/day; • )  or saline (o )  for 1 
week on the plasma concentra­
tions o f cholesterol (left panels) 
and triglycerides (right panels) in 
rats. Blood samples were taken 
daily between 10 AM and noon. 
Osmotic minipumps containing 
IL1 or saline were implanted in- 
traperitoneally between 2 and 4 
PM on day 0 (arrow). Data are 
presented as m ean±SEM  o f five 
to seven rats. Asterisks mark sig­
nificant differences between IL1- 
and saline-treated rats: *p<0.05, 
*’p <0.005, “ ‘p <0.0005 by Stu­
dent's t test.
2 )r 4.0 fig rhIL-l/3/day reduced body weight gain 
( OVA days 1-7, 2.0 fig, p < 0.0005; 4.0 fig, p<0.05). 
V -ht loss was already maximal on the first day of 
ii ion. Daily body weight change in rh IL -l /3 - trea ted
i reached approximately initial levels by the third day 
0! fusion. Thereafter  the rate of daily body weight
ii use was essentially the same for both rhIL-1/3- and 
s e-treated groups of animals. Continuous infusion of
i 1/3 at doses of 0.5, 2.0, and 4.0 ¿¿g/day into rats had 
n» it'ect on total daily fluid intake (data not shown).
tal temperature changes (Figure 3). Saline-treated 
rais maintained a virtually constant rectal temperature 
throughout the entire infusion period. Infusion of 
rhl1 -1)3 produced an increase in rectal temperature
(ANOVA days 1-7, 0.5 f ig ,p < 0.005; 2.0 fig ,/?<0.05; 4.0 
Mg. /x0 .05 ) .  Tem pera ture  peaked 1 day after implan­
t a t io n  of pumps infusing rhIL-1/3 at a rate of 0.5 and 2.0 
Mg d a y  but had returned to values of saline-infused rats 
011 d a y  3. From then on values of rh IL -l /3 - trea ted  rats 
and saline-treated rats were similar. The mean maximal 
mcrease in tem perature induced by 2.0 fig rhIL-l/3/day 
(+1 C) was significantly greater ( p < 0.05) than that 
induced by infusion of 0.5 fig rhIL-l/3/day ( + 0.9°C). At 
a dose of 4.0 fig rhIL-l/3/day, rectal tem perature also 
peaked on day 1 ( +  1.3°C) and then gradually declined 
but remained elevated throughout the whole experi­
mental period. Post hoc analysis of the individual groups
in this experiment revealed that rectal temperatures 
were significantly elevated on days 1, 2, 3, 4, and 7.
Lipoprotein analysis. Figure 4 shows the lipoprotein 
profile in plasma on day 5 of treatment with 2.0 fig 
rhIL-l/3/day or saline. The decrease in total plasma 
cholesterol ( —32.8%) was accounted for by a decrease 
of cho les te ro l  in all m ajor l ipopro te in  fractions 
(VLDL4-IDL, 0.13±0.02 versus 0.25±0.04 mmol/1, 
/?<0.05; LDL, 0.36±0.04 versus 0.54±0.03 mmol/1, 
p < 0 .0 0 5 ;  and H D L , 0 .38±0.01  versus 0 .56±0 .02  
mmol/1,/?<0.0005; rhIL-1/3 versus saline). The decrease 
in plasma levels of triglycerides was reflected by a 
decrease in V L D L + ID L  triglycerides.
Determination o f  cholesterol esterification rate. The 
percentage of unesterified cholesterol to total choles­
terol in plasma was not different between rats treated 
with 2.0 fig rhIL-l/3/day (35.4±1.0%) or with saline 
(32.6±1.9%). The cholesterol esterification rate m ea­
sured during incubation of plasma for 1 and 3 hours also 
did not differ significantly between both groups: at 1 
h o u r  the  ra te  of ch o le s te ro l  e s te r if ica t ion  was 
0.056±0.008 mmol/1 • h r -1 in the rhIL-1/3 group and 
0.057±0.007 m m o l/1 -h r”1 in the control group; at 3 
hours these values were 0.060±0.010 and 0.062±0.012 
mmol/1 • h r " 1, respectively.
Total lipolytic, HL, and LP L activities in postheparin 
plasma samples. On day 7 of the 2.0 fig rhIL-1/3 exper-
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iment, total lipolytic, HL, and LPL activities were 
determined in postheparin plasma samples. Total li­
polytic activity did not differ significantly between both 
groups (41.9±2.1 versus 43.2±1.2 fimol free fatty acids 
[FFA]/hr • m l"1 plasma, rhIL-1/3 versus saline). rhIL-1/3 
treatment caused a significant decrease in HL activity 
(24.7±1.7 versus 29.8±0.5 ¿¿mol F F A /h r  • m l"1 plasma, 
rhIL-1/3 versus saline, p<0.05), whereas rhIL-1/3 caused 
a significant increase in LPL activity (17.2±0.8 versus 
13.4±1.1 fimo\ F F A /h r  -m l" 1 plasma, rhIL-1/3 versus 
saline, p < 0.05). During rhIL-1/3 infusion the ratio of 
H L to LPL was significantly decreased (1.45±0.10 ver­
sus 2.29±0.19,/?<0.005).
Effects o f  Food Restriction on Plasma Levels o f  
Cholesterol and Triglycerides
As expected, the food intake of the food-restricted 
rats mimicked that of the rats given 2.0 /xg rhIL-l/3/day 
(Figure 5A). Rats that were fed the same amount of 
food as that consumed by rh IL -l /3 - trea ted  rats showed 
a significantly different pattern of body weight change in 
comparison with control rats fed ad libitum (Figure 5B; 
A N O V A  days 1-7,/?<0.0005). On day 1 food-restricted 
rats showed a body weight decrease of 16.4± 1.5 g while 
control rats fed ad libitum lost 3.0±2.0 g (food-restrict­
ed versus control rats, p <0.0005). On day 2 food- 
restricted rats lost 5.7±1.0 g and control rats gained 
2.8± 1.1 g ( p <0.0005). Thereafter, daily body weight 
gain was no longer decreased in the food-restricted rats.
Food restriction induced a slight but significant de­
crease in plasma cholesterol levels compared with val­
ues in rats fed ad libitum (A N O V A  days 1—7, p <0.05; 
Figure 5C). Statistically significant differences in plasma 
cholesterol levels between both groups of rats were 
observed on day 3 (1.62±0.04 versus 1.88±0.06 mmol/1, 
rhIL-1/3 versus saline, p<0 .05)  and day 4 (1.62±0.06 
versus 1.89±0.05 mmol/1, rhIL-1/3 versus saline, 
p < 0.05). Restriction of food intake had no effects on 
plasma concentrations of triglycerides (Figure 5D).
Discussion
The present study demonstrates that continuous in­
fusion of rhIL-1/3 in doses as low as 2.0 and 4.0 /xg/day 
profoundly lowers plasma cholesterol concentrations in 
rats. Infusion of 0.5 /xg rhIL-l/3/day did not significantly 
change plasma cholesterol levels. rhIL-1/3 was infused 
for 7 days by osmotic minipumps implanted in the 
peritoneal cavity. Previously it has been shown that 
under these conditions IL-1 remains bioactive and 
bioavailable for at least 1 week.29 The cholesterol- 
lowering effect of the higher doses of IL-1 persisted 
until the end of the study. Interestingly, the decrease in 
plasma cholesterol levels was not observed before the 
second day of treatment with IL-1. Lipoprotein analysis 
on day 5 of the 2.0 /xg rhIL-1/3 experiment revealed that 
the decrease in the total plasma cholesterol level was 
due to a decrease in cholesterol levels in all lipoprotein 
fractions.
O ur study also shows that triglyceride levels in p la s m a  
obtained from nonfasted rats were significantly de­
creased during long-term administration of 2.0 and 4.0 
fig rhIL-l/3/day and that at the end of the infusion
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pti od this effect was diminishing. In contrast, Feingold 
et i!27 showed that short-term intravenous administra- 
tion of 1 g IL-1 rapidly increased serum triglyceride 
levels in rats. This elevation in triglyceride levels per- 
sisted for 17 hours and was accompanied by an increase 
01 Hepatic triglyceride secretion and de novo fatty acid 
synthesis, whereas the clearance of triglyceride-rich 
lipoproteins was unaffected by IL-1. In that study IL-1 
had no effect on serum cholesterol levels. Argiles et al,28 
using an even higher dose of IL-1 (20 fig), also found an 
•ncrease in triglyceride levels after short-term adminis­
tration of the cytokine in rats, but these workers failed 
to demonstrate any effect on hepatic lipogenesis. In 
contrast with both studies with rats, Del Rey and
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Besedovsky34 found that injection of 0.25 /xg IL-1 in 
diabetic mice caused a marked reduction in serum 
triglyceride levels.
We confirm previous findings that administration of 
IL-1 induces dose-dependent fever in rats.35 In our 
study, infusion of rats with 4.0 /xg rhIL-l/3/day induced 
prolonged fever, whereas at the lower doses of rhIL-1/3 
(2.0 and 0.5 /xg/day) temperatures were elevated only 
on the first 2 days of infusion. rhIL-1/3 treatment was 
also associated with a decrease in food intake and body 
weight gain, which is in good agreement with previous 
reports.36-38 The effect of rhIL-1/3 on body weight gain 
was present during the first 2 days of infusion but had 
been lost by day 3 of treatment. This is in line with 
studies demonstrating that tolerance to the anorectic 
effects of IL-1 develops within a few days.29*30
In fasting rats plasma cholesterol and triglyceride 
levels are lower than in rats with unrestricted access to 
food.39 To clarify whether the effects of IL-1 on plasma 
cholesterol and triglyceride levels could be explained 
solely by the reduction of food intake during rhIL-1 ¡3 
treatment, we investigated the effects of food consump­
tion restricted to the same level as in the 2.0 fig rhIL-1/3 
experiment on plasma cholesterol and triglyceride con­
centrations. This experiment revealed that such a re ­
duction of food intake had no effect on plasma triglyc­
eride concentrations, whereas plasma cholesterol levels 
were moderately lowered. Therefore, it can be con­
cluded that it is highly unlikely that the decrease in 
plasma triglyceride levels observed during long-term 
IL-1 infusion is caused by decreased food intake and 
that the observed decrease in food intake cannot com­
pletely explain the profound decrease of plasma choles­
terol levels during IL-1 administration.
Intravenous injection of lipopolysaccharide or TN F 
causes a decrease in the activity of the LCAT enzyme in 
nonhuman primates.40*41 It has been suggested that this 
decrease in LCAT activity after T N F administration is 
causally related to the occurrence of hypocholester- 
olemia after injection of this cytokine in nonhuman 
primates. However, it is unlikely that in our study a 
decrease in LCAT activity was the cause of the hypo- 
cholesterolemia during IL-1 treatment because the ra-
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tio of free cholesterol to esterified cholesterol in the 
plasma of rats infused with 2.0 fig rhIL-l/3/day was not 
significantly different from control rats, which suggests a 
normal cholesterol esterification rate in vivo. Indeed, 
cholesterol esterification rates determined in vitro were 
similar for rh IL -l /3 - trea ted  and control rats.
Thus, other mechanisms causing hypocholesterolemia 
and hypotriglyceridemia should be considered. In pa­
tients with sepsis, plasma concentrations of apolipopro- 
tein B, the major structural protein of cholesterol- 
carrying lipoproteins in humans, are decreased.5 O ther 
investigators have shown that IL-1 decreases the secre­
tion of apolipoprotein B by Hep G2 cells.42 Therefore it 
might be that hypocholesterolemia during long-term 
IL-1 treatment is caused by impaired secretion of 
apolipoprotein B by hepatocytes. With respect to the 
metabolism of triglycerides, we found that although 
small reciprocal changes were observed in the activities 
of LPL and HL, the total postheparin lipolytic activity in 
plasma on day 7 of the 2.0 fig rhIL-1/3 experiment was 
similar in rhIL-1/3- and saline-treated rats. With the 
assumption that the clearance of triglycerides in plasma 
is largely determined by this lipolytic activity, it seems 
unlikely that the decrease in triglyceride levels during 
IL-1 treatment is caused by an increased clearance of 
triglyceride-rich lipoproteins. We suggest that the de­
crease in triglyceride levels is due to a diminished 
secretion of nascent VLDL.
A  decrease in plasma cholesterol level has also been 
observed during treatment with o ther cytokines. A d­
ministration of macrophage colony-stimulating factor 
(M-CSF) to nonhuman primates and normocholester- 
olemic and hypercholesterolemic rabbits results in de­
creases in plasma cholesterol levels.43 In humans trea t­
ment with M-CSF also induces a sharp decrease in 
plasma cholesterol levels.44 Hypocholesterolemia in hu­
mans is also observed during treatment with granulo­
cy te -m acrophage  co lony-s t im ula ting  fac to r  (G M - 
CSF).45’46 The mechanism of the hypocholesterolemia 
after administration of these hematopoietic growth fac­
tors is unknown. In this respect it is noteworthy that 
receptors for GM-CSF are present on monocytes/mac­
rophages.47 This finding has led to the suggestion that 
GM-CSF causes hypocholesterolemia indirectly by stim­
ulating Kupffer cells to produce a cholesterol-lowering 
factor.45*48 Because GM -CSF stimulates the production 
of IL-1 from normal human peripheral blood mononu­
clear cells in vitro49 and because long-term IL-1 admin­
istration has the potential to lower plasma cholesterol 
levels (this study), it might be that the decrease of 
plasma cholesterol levels observed during treatment 
with GM-CSF is caused by (intrahepatic) release of 
IL-1. Alternatively, because IL-1 induces GM-CSF se­
cretion,50 it might be that IL-1 causes hypocholester­
olemia by inducing GM-CSF secretion.
Hypertriglyceridemia is frequently present during in­
fection in both humans and laboratory animals.8-12 
There are as yet no convincing data that IL-1 does 
mediate the hypertriglyceridemia of infection. Except 
for studies of rabbits,1-2 most reports of cholesterol 
metabolism during bacterial infections agree that 
plasma cholesterol levels are decreased during the 
febrile phase of bacterial infections.3-8 W hether IL-i 
released from the inflammatory site or produced locally 
by endotoxin-stimulated Kupffer cells plays a role as a 
mediator in the lowering of plasma cholesterol levels 
during infections remains to be investigated.
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